Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 266Neoplasms 231Carcinoma, Non-Small-Cell Lung 209Colorectal Neoplasms 155Prostatic Neoplasms 148Lung Neoplasms 121Neoplasm Metastasis 112Ovarian Neoplasms 105Multiple Myeloma 98Pancreatic Neoplasms 91Leukemia, Myeloid, Acute 82Squamous Cell Carcinoma of Head and Neck 76Endometrial Neoplasms 67Melanoma 66Stomach Neoplasms 63Glioblastoma 61Recurrence 58Brain Neoplasms 56Carcinoma, Hepatocellular 53Urinary Bladder Neoplasms 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Head and Neck Neoplasms 51Carcinoma, Renal Cell 51Triple Negative Breast Neoplasms 50Lymphoma 50Hematologic Neoplasms 47Glioma 46Esophageal Neoplasms 46Colonic Neoplasms 46Small Cell Lung Carcinoma 43

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lethal Congenital Contracture Syndrome 2 × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡